Individualized Estimated Glomerular Filtration Rate-based Renal Function Association With Cisplatin Treatment Completion in Cervical Cancer
Toxicity-related discontinuation remains problematic in cisplatin-based cervical cancer treatment. This study aimed to evaluate the association between renal function assessed using individualized estimated glomerular filtration rate (eGFR) and the completion rate of cisplatin-based concurrent chemoradiotherapy (CCRT) in patients with cervical cancer. This retrospective study included patients with cervical cancer who received CCRT with cisplatin (40 mg/m A total of 80 patients were included, of whom 68 (85%) completed the planned cisplatin regimen. Although all patients had CGCCr ≥60 ml/min, individualized eGFR assessment revealed that 19% of patients had eGFR <60 ml/min. The proportion of patients with an eGFR <60 ml/min was significantly higher in the non-completion group (58% Patients with an individualized eGFR <60 ml/min showed significantly higher cisplatin non-completion rates even when their CGCCr was ≥60 ml/min. These findings suggest that individualized eGFR assessment, in addition to CGCCr, should be considered for optimizing cisplatin dosing in cervical cancer CCRT.